secwatch.observer — SEC 8-K summary
======================================

Issuer:     Co-Diagnostics, Inc. (CODX)
CIK:        0001692415
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001493152-22-013017
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Co-Diagnostics reports Q1 revenue $22.7M, net income $11.7M ($0.34 EPS); no guidance given
--------------------------------------------------------------------------------

- Q1 revenue $22.7M, record first quarter; net income $11.7M ($0.34 diluted EPS) vs $7.9M a year ago.
- Gross profit $19.4M (85.5% margin); operating income $9.8M down from $10.3M on higher R&D.
- Cash, equivalents, and marketable securities $97.4M, up $7.5M from Dec 2021.
- Co-Dx PCR home testing platform progressing toward FDA submission later this year.
- No quarterly guidance provided due to diminished COVID-19 test sales forecasting ability.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/0001493152-22-013017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-013017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer